Abiraterone Accord for Metastatic castration-resistant prostate cancer
Quick answer: Abiraterone Accord is used for Metastatic castration-resistant prostate cancer as part of a androgen biosynthesis inhibitor (cyp17 inhibitor) treatment regimen. Selectively inhibits CYP17A1 enzyme, blocking androgen biosynthesis in testes, adrenals, and prostate tumor tissue The specific dosing for Metastatic castration-resistant prostate cancer is determined by your prescriber based on individual factors.
Why is Abiraterone Accord used for Metastatic castration-resistant prostate cancer?
Abiraterone Accord belongs to the Androgen biosynthesis inhibitor (CYP17 inhibitor) class. Selectively inhibits CYP17A1 enzyme, blocking androgen biosynthesis in testes, adrenals, and prostate tumor tissue This action makes it useful for treating or managing Metastatic castration-resistant prostate cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Abiraterone Accord is the right choice for a specific patient depends on the type and severity of Metastatic castration-resistant prostate cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Metastatic castration-resistant prostate cancer
Common adult dosing range: 1000 mg once daily with prednisone 5 mg twice daily. The actual dose for Metastatic castration-resistant prostate cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Abiraterone Accord medicine page.
What to expect
Abiraterone Accord treatment for Metastatic castration-resistant prostate cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Metastatic castration-resistant prostate cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Abiraterone Accord is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Androgen biosynthesis inhibitor (CYP17 inhibitor) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Abiraterone Accord
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Abiraterone Accord full prescribing information · All Androgen biosynthesis inhibitor (CYP17 inhibitor) alternatives
Frequently asked questions
How effective is Abiraterone Accord for Metastatic castration-resistant prostate cancer?
Effectiveness varies by individual response, dose, and severity. Abiraterone Accord is one of several treatment options for Metastatic castration-resistant prostate cancer, supported by clinical evidence within the androgen biosynthesis inhibitor (cyp17 inhibitor) class. Discuss expected response with your prescriber.
How long do I need to take Abiraterone Accord for Metastatic castration-resistant prostate cancer?
Treatment duration depends on the nature of Metastatic castration-resistant prostate cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Abiraterone Accord when used for Metastatic castration-resistant prostate cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Abiraterone Accord for Metastatic castration-resistant prostate cancer?
Yes. Multiple medicines and non-drug options exist for Metastatic castration-resistant prostate cancer. Alternatives within the androgen biosynthesis inhibitor (cyp17 inhibitor) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.